Ionis Pharmaceuticals Shares Plunge After Heart Drug Fails Late-Stage Trial

Shares of Ionis Pharmaceuticals (NASDAQ: IONS) plummeted in pre-market trading after the company and its partner AstraZeneca announced their late-stage clinical trial for the drug eplontersen failed to meet its primary goal in treating a progressive heart condition.

Trial Fails Primary Endpoint

The Phase 3 CARDIO-TTRansform study did not achieve its primary efficacy endpoint, which was a composite measure of cardiovascular mortality and recurrent cardiovascular events through week 140 compared to a placebo, the companies reported. The trial evaluated eplontersen in 1,432 patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a serious and often fatal disease.

While the drug's safety profile was consistent with previous data and a pre-specified subgroup analysis showed a nominally significant result, the failure to meet the main objective represents a significant clinical setback for the program. The trial was one of the most extensive ever conducted for ATTR-CM, involving 130 sites across 20 countries.

Market Impact and Strategic Setback

Investors reacted swiftly to the news, sending Ionis stock down 14.0% to $72.60 in pre-open trading. The outcome deals a major blow to the company's growth outlook, as a successful result was considered a key catalyst for expanding eplontersen's commercial footprint.

Ad

The drug, marketed as WAINUA, is approved for a related nerve condition, but the ATTR-CM indication represented a much larger and more lucrative market opportunity. This failure now casts significant doubt on the drug's ability to compete in the broader cardiomyopathy space and challenges a core part of the company's pipeline narrative.

Competitive Landscape Shifts

The trial results effectively strengthen the market position of competitors in the ATTR treatment landscape. The failure of eplontersen to prove its efficacy in cardiomyopathy removes a near-term threat to established players.

Key rival Alnylam Pharmaceuticals, which markets the approved ATTR-CM therapy Amvuttra, is a notable beneficiary of the news. Other companies in the space, such as BridgeBio and Pfizer, also stand to gain from the diminished competitive pressure.